Mallorca.
Tumors with high PTBP1 didn’t have fewer immune cells — instead, their T cells were more dysfunctional/exhausted, explaining the poor response to immunotherapy.
(6/7)
Tumors with high PTBP1 didn’t have fewer immune cells — instead, their T cells were more dysfunctional/exhausted, explaining the poor response to immunotherapy.
(6/7)
This suggests PTBP1 impacts immune function qualitatively (e.g., antigen presentation, T cell state) rather than simply reducing immune cell numbers.
(5/7)
This suggests PTBP1 impacts immune function qualitatively (e.g., antigen presentation, T cell state) rather than simply reducing immune cell numbers.
(5/7)
Patients with high PTBP1 expression ❌ did not respond to immunotherapy and showed shorter progression-free and overall survival.
(4/7).
Patients with high PTBP1 expression ❌ did not respond to immunotherapy and showed shorter progression-free and overall survival.
(4/7).
Interestingly, when PTBP1 was removed, the cells reactivated HLA expression — proteins essential for immune cells to recognize and attack tumor cells.
(3/7)
Interestingly, when PTBP1 was removed, the cells reactivated HLA expression — proteins essential for immune cells to recognize and attack tumor cells.
(3/7)
But why do some respond while others don’t?
We set out to identify genes linked to immune evasion in TNBC — and that’s how we found PTBP1.
(2/7)
But why do some respond while others don’t?
We set out to identify genes linked to immune evasion in TNBC — and that’s how we found PTBP1.
(2/7)